share_log

Citigroup Downgrades Mersana Therapeutics to Neutral, Lowers Price Target to $1

Benzinga ·  Jul 28, 2023 09:17

Citigroup analyst Ashik Kurian downgrades Mersana Therapeutics (NASDAQ:MRSN) from Buy to Neutral and lowers the price target from $10 to $1.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment